Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
serplulimab + gemcitabine + nab-paclitaxel + stereotactic body radiation therapy
- Development stage
- Unknown
- Lead developer
- Henlius
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This combination regimen is a multi-modal therapeutic approach being evaluated for the first-line treatment of metastatic or locally advanced pancreatic ductal adenocarcinoma (PDAC). It consists of the anti-PD-1 monoclonal antibody serplulimab, the chemotherapy agents gemcitabine and nab-paclitaxel (collectively known as the GnP regimen), and stereotactic body radiation therapy (SBRT). Serplulimab, developed by Henlius, functions as a checkpoint inhibitor to enhance the immune system's anti-tumor response by blocking the PD-1 pathway. Gemcitabine and nab-paclitaxel provide a cytotoxic backbone that inhibits DNA synthesis and microtubule function, respectively. SBRT is employed as a high-dose local treatment intended to induce immunogenic cell death and potentially synergize with the immunotherapy component. The regimen is currently being investigated in Phase II and Phase III clinical trials sponsored by West China Hospital of Sichuan University.
- Other names
- GnP-West China Hospital-pancreatic ductal adenocarcinomaSerplulimab + SBRT + GnPGnP + SBRT + Serplulimab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on serplulimab + gemcitabine + nab-paclitaxel + stereotactic body radiation therapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on serplulimab + gemcitabine + nab-paclitaxel + stereotactic body radiation therapy.